177 Lu-PSMA-617 radioligand therapy for biohemically recurrent prostate cancer

⋅ Prostate-specific membrane antigen (PSMA) is expressed by unfavorable types of prostate        cancer (PCa). ¹⁷⁷Lu-PSMA-617 radioligand therapy was an effective treatment for patients with metastatic castration-resistant (mCR) PCa who have failed established systemic treatments.

⋅           In this case report, ¹⁷⁷Lu-PSMA-6!7 radioligand therapy was instituted for the third biochemical recurrence (BCR) and the outcome was compared with those of two previous episodes of BCR.            

 ⋅          ¹⁷⁷Lu-PSMA-617 radioligand therapy for the third biochemical recurrence (BCR) lowered PSA from 0.6 ng/ml to unmeasurable values six months later. The first and second BCR had been treated with salvage radiotherapy and abiraterone. These treatments had only given a partial and transitory reduction of PSA.

⋅           It is questionable that it is best to reserve ¹⁷⁷Lu-PSMA-617 radioligand therapy for only patients with mCRPCa who have failed systemic treatments.